Amgen says Imdelltra extended survival; Parker Institute adds new leaders

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy

Amgen says Imdelltra extended survival; Parker Institute adds new leaders

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

Amgen's Phase III trial of Imdelltra meets primary endpoint for SCLC

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for treating SCLC.The post Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC appeared first on Clinical Trials Arena.

Imdelltra May Improve Survival in Small Cell Lung Cancer

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Amgen Says Imdelltra Extended Survival; Parker Institute Adds New Leaders

Today, a brief rundown of news involving Amgen and the Parker Institute, as well as updates from J&J, Alzheon and Amylyx Pharmaceuticals that you may have missed. Amgen’s bispecific cancer antibody Imdelltra helped people with previously treated small cell lung cancer live longer than those who received chemotherapy, the company said Friday. The conclusion was made at an interim analysis of the Phase 3 DeLLphi-304 trial, which enrolled 500 peopl…

Breakthrough: New Cancer Drug IMDELLTRA Outperforms Standard Treatment in Survival Study

Latest Phase 3 data reveals IMDELLTRA significantly improves survival in aggressive small cell lung cancer, marking major advancement in treatment options. Full analysis inside.